Connor, Clark & Lunn Investment Management (CC&L)
CTXR icon

Connor, Clark & Lunn Investment Management (CC&L)’s Citius Pharmaceuticals CTXR Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-6,910
Closed -$351K – 1102
2021
Q3 		$351K Buy
+6,910
New +$347K ﹤0.01% 841

Other funds holding CTXR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s CTXR Position: Q4 2021 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Citius Pharmaceuticals (CTXR) in Q4 2021, closing a stake of 6,910 shares — an estimated $351K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in CTXR in Q3 2021 and held it in 1 quarter. The position peaked at $351K in Q3 2021. 76 funds tracked by Wall St. Rank hold CTXR as of Q4 2021.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Citius Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 6,910 Citius Pharmaceuticals shares in Q4 2021, an estimated $351K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Citius Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Citius Pharmaceuticals position peaked at $351K in Q3 2021.
  • 76 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q4 2021.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2021, filed 10 Feb 2022.